I’ve coated two chapter tales earlier than. Not from the standard angle of what occurred and why; for every, I dug deeper into who might win from the wreckage.
The Magellan Aerospace story led me to Howmet. The IKEA retailer closures pointed me to Goal. This week’s Chapter 11 submitting from Focus Issue maker Synergy CHC Corp. factors me squarely to Reckitt Benckiser (RBGLY).
Synergy CHC filed for chapter on September 4, 2026, within the U.S. Chapter Court docket for the District of Columbia, TheStreet reported.
Costco informed the corporate again in July that it will be discontinuing Focus Issue merchandise after a 16-year relationship. You see that one determination? It price Synergy roughly 58% of its complete 2025 web income, triggered an $18.9 million debt acceleration from its lender, and made Chapter 11 inevitable.
RBGLY presently trades at $14, down 10.62% year-to-date, based on Yahoo Finance.
How a 58% income focus turns into a deadly single level of failure
The Synergy CHC scenario exhibits simply how rapidly retail focus can turn into a threat. Focus Issue is a purposeful beverage model with a 25-year legacy, having fun with established distribution within the U.S., Canada, and Mexico, and distribution throughout Walmart, Walgreens, Amazon, and BJ’s.
The corporate’s a mind complement with nutritional vitamins, minerals, and neuro-nutrients. It carries a “#1 Pharmacist Really useful” declare from the 2025-2026 U.S. Pharmacy Occasions survey for reminiscence help. None of that mattered as soon as Costco made its determination.
Extra Retail:
“Costco accounted for about 58% of the Firm’s web income in the course of the fiscal yr ended December 31, 2025,” the SEC submitting said. “The Firm expects Costco’s determination to have a fabric adversarial impact on the Firm’s enterprise, outcomes of operations, liquidity, and monetary situation.”
Costco didn’t give a public purpose for dropping the model. It didn’t must. It is a retailer that strikes merchandise in bulk, and it made its vendor determination for no matter purpose.
The $18.9 million debt acceleration that adopted confirmed Synergy had no monetary cushion to outlive even a short lived income disruption of this magnitude.
Why I feel Reckitt’s Neuriva is the plain beneficiary
Three structural benefits make Reckitt the clearest winner.
-
Neuriva is already in Costco’s system. The Neuriva Mind Complement Unique (50 capsules) presently retails at Costco for $43.99. Reckitt doesn’t must win a vendor slot or navigate Costco’s notoriously demanding provider necessities. It’s already accredited, built-in, and promoting. Scaling quantity inside an current provider relationship is operationally simple.
-
Reckitt’s product portfolio matches neatly into the place Costco needs to go. Costco members are likely to gravitate towards premium wellness merchandise backed by established manufacturers and analysis. Reckitt has been aggressively increasing Neuriva, with merchandise together with Neuriva Plus, Neuriva Extremely, and Neuriva Reminiscence 3D. I see these premium formulations align with Costco’s push towards higher-margin well being options much better than the legacy Focus Issue lineup.
-
The regulatory historical past issues, too. Focus Issue has confronted FTC settlements and shopper class-action lawsuits difficult its efficacy claims. Reckitt builds Neuriva’s advertising round clinically studied substances and GMO-free formulations.
